Abstract
We have redesigned cationic liposomes by using a combination of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol to enhance the in vitro and in vivo effectiveness of antisense raf oligodeoxyribonucleotide (ODN). Circulating ODNs carried in vivo by liposomes were intact for at least 24 h, while free ODNs were undetectable after 5 min. Liposome-encapsulated antisense raf ODN (LE-ATG-AS) inhibited Raf-1 protein expression in vitro and in vivo. Furthermore, radioresistant tumor cells treated with LE-ATG-AS raf ODN were sensitized to ionizing radiation. These data provide new information for the delivery and potency of antisense ODN in vivo, and support the use of LE-ATG-AS raf ODN for gene therapy of radioresistant cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gokhale, P., Soldatenkov, V., Wang, FH. et al. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther 4, 1289–1299 (1997). https://doi.org/10.1038/sj.gt.3300543
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300543
Keywords
This article is cited by
-
Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft
Journal of Translational Medicine (2011)
-
Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems
Cancer Gene Therapy (2011)
-
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN
Cancer Immunology, Immunotherapy (2007)
-
RAF antisense oligonucleotide as a tumor radiosensitizer
Oncogene (2003)
-
Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1
Oncogene (2002)